Mechanism of Apoptosis and Inhibition of Tumor Progression and Metastasis by Par-

Par-细胞凋亡及抑制肿瘤进展和转移的机制

基本信息

  • 批准号:
    7909261
  • 负责人:
  • 金额:
    $ 31.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-01 至 2011-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Prostate apoptosis response-4 protein (Par-4; also known as PAWR) is a leucine zipper domain protein that is conserved in vertebrates. During the previous funding period, we showed the core effector domain of Par-4 (amino acids 137-195, designated the SAC domain) is necessary and sufficient to induce apoptosis. Interestingly, both Par-4 and its SAC domain induce apoptosis selectively in cancer cells, but not in normal cells. Although ectopic Par-4 and the SAC domain have long been thought to effect apoptosis by acting within the cell nucleus to inhibit NF-kappaB, our recent transient transfection studies unexpectedly displayed apoptosis in neighboring cells that did not express the Par-4 or SAC plasmid. Moreover, conditioned medium (CM) from Par-4 transfected cells induced apoptosis when applied to cancer cells, but not to normal cells; this implies over-expression of Par-4 leads to the secretion of a pro-apoptotic activity. Both Par-4 and the SAC protein were detected in the CM by Western blot analysis, and the apoptotic activity in this CM was neutralized by antibodies against Par-4. The apoptotic activity was diminished in the CM from Par-4 transfectants treated with brefeldin A, indicating Par-4 and SAC secretion (or sPar-4 and sSAC, respectively) occurs by the classical pathway (i.e., from the endoplasmic reticulum to the Golgi, and then to the cell membrane). Importantly, CM from normal and cancer cells contains endogenous Par-4, of which the levels increase upon treatment with TRAIL (a short term exposure that is insufficient to produce apoptosis), thereby indicating secretion is physiologically relevant, and not an artifact associated with over-expression of the Par-4 and SAC constructs. Based on these data, we hypothesize endogenous and exogenous sPar-4 and sSAC exert cancer-specific apoptotic effects via both intracellular and extracellular mechanisms. We will address this hypothesis from a mechanistic perspective, characterizing secreted Par-4 and SAC in prostate cancer cells, and clarifying the means by which they selectively initiate apoptosis in cancer cells. Specifically, we will 1) Delineate the mechanism of Par-4/SAC secretion and apoptosis by sPar-4/sSac in prostate cancer cells; 2) Test the growth suppressive effects of sPar-4 and sSAC domain in prostate cancer models; and 3) Study the inter-dependence of extracellular and intracellular Par-4 in inducing apoptosis in cancer cells. As our recent studies indicate Par- 4 and its SAC domain are secreted, and that recombinant (r) Par-4 or rSAC can induce apoptosis when applied exogenously to cells, these data may hold significant clinical relevance. Our results introduce the novel prospect of using sPar-4 or sSAC to induce apoptosis, not only in local or superficially confined tumors into which Par-4 or SAC can be readily delivered intratumorally, but also to distant metastases by intravenous injection or bone-marrow transplantation, which we will explore in this proposal. PUBLIC HEALTH RELEVANCE: Our research focuses on the secreted forms of Par-4 and it core effector domain SAC, both of which selectively induce apoptosis in cancer cells. We will study these two proteins from a mechanistic perspective both in vitro and in vivo, characterizing secreted Par-4 and SAC in prostate cancer cells, and clarifying the means by which they selectively initiate apoptosis in cancer cells. The proposed science will explore the novel prospect of using sPar-4 or sSAC to induce apoptosis, not only in local or superficially confined tumors into which Par-4 or SAC can be readily delivered intratumorally, but also to distant metastases by intravenous injection or bone-marrow transplantation.
描述(由申请人提供):前列腺凋亡反应-4蛋白(Par-4;也称为PAWR)是一种在脊椎动物中保守的亮氨酸拉链结构域蛋白。在之前的资助期间,我们表明Par-4的核心效应结构域(氨基酸137-195,命名为SAC结构域)是诱导细胞凋亡所必需和足够的。有趣的是,Par-4及其SAC结构域都选择性地在癌细胞中诱导凋亡,但在正常细胞中不诱导凋亡。尽管异位Par-4和SAC结构域长期以来被认为通过在细胞核内作用以抑制NF-κ B来影响凋亡,但我们最近的瞬时转染研究意外地显示了不表达Par-4或SAC质粒的邻近细胞中的凋亡。此外,来自Par-4转染细胞的条件培养基(CM)在应用于癌细胞而非正常细胞时诱导凋亡;这意味着Par-4的过表达导致促凋亡活性的分泌。通过Western印迹分析在CM中检测到Par-4和SAC蛋白,并且该CM中的凋亡活性被针对Par-4的抗体中和。来自用布雷菲德菌素A处理的Par-4转染子的CM中的凋亡活性降低,表明Par-4和SAC分泌(或分别为sPar-4和sSAC)通过经典途径(即,从内质网到高尔基体,然后到细胞膜)。重要的是,来自正常细胞和癌细胞的CM含有内源性Par-4,其水平在用TRAIL处理(不足以产生细胞凋亡的短期暴露)后增加,从而表明分泌是生理学相关的,而不是与Par-4和SAC构建体的过表达相关的伪影。基于这些数据,我们假设内源性和外源性sPar-4和sSAC通过细胞内和细胞外机制发挥癌症特异性凋亡作用。我们将从机制的角度解决这一假设,表征前列腺癌细胞中分泌的Par-4和SAC,并阐明它们选择性启动癌细胞凋亡的方法。具体而言,我们将1)描述前列腺癌细胞中sPar-4/sSac分泌Par-4/SAC和凋亡的机制; 2)测试前列腺癌模型中sPar-4和sSAC结构域的生长抑制作用;以及3)研究细胞外和细胞内Par-4在诱导癌细胞凋亡中的相互依赖性。由于我们最近的研究表明Par- 4及其SAC结构域是分泌的,并且重组(r)Par-4或rSAC在外源性应用于细胞时可以诱导细胞凋亡,因此这些数据可能具有显著的临床相关性。我们的研究结果介绍了新的前景,使用sPar-4或sSAC诱导凋亡,不仅在局部或表面局限的肿瘤,其中Par-4或SAC可以很容易地交付到肿瘤内,而且通过静脉注射或骨髓移植,我们将探讨在这个建议的远处转移。公共卫生相关性:我们的研究集中在Par-4的分泌形式及其核心效应结构域SAC,这两者都选择性地诱导癌细胞凋亡。我们将从体外和体内机制的角度研究这两种蛋白质,表征前列腺癌细胞中分泌的Par-4和SAC,并阐明它们选择性启动癌细胞凋亡的方法。这项研究将探索使用sPar-4或sSAC诱导细胞凋亡的新前景,不仅在局部或表面局限的肿瘤中,Par-4或SAC可以很容易地在肿瘤内递送,而且还可以通过静脉注射或骨髓移植诱导远处转移。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Vivek M Rangnekar其他文献

Vivek M Rangnekar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Vivek M Rangnekar', 18)}}的其他基金

Suppression of Prostate Tumor Growth and Metastasis by Inhibition of Vimentin
通过抑制波形蛋白来抑制前列腺肿瘤的生长和转移
  • 批准号:
    9288139
  • 财政年份:
    2015
  • 资助金额:
    $ 31.88万
  • 项目类别:
Suppression of Prostate Tumor Growth and Metastasis by Inhibition of Vimentin
通过抑制波形蛋白来抑制前列腺肿瘤的生长和转移
  • 批准号:
    8962894
  • 财政年份:
    2015
  • 资助金额:
    $ 31.88万
  • 项目类别:
Regulation of Par-4 Secretion in Normal Cells for Paracrine Action in Tumor Cells
正常细胞中 Par-4 分泌的调节对肿瘤细胞中旁分泌作用的影响
  • 批准号:
    8828616
  • 财政年份:
    2014
  • 资助金额:
    $ 31.88万
  • 项目类别:
Regulation of Par-4 Secretion in Normal Cells for Paracrine Action in Tumor Cells
正常细胞中 Par-4 分泌的调节对肿瘤细胞中旁分泌作用的影响
  • 批准号:
    8690405
  • 财政年份:
    2014
  • 资助金额:
    $ 31.88万
  • 项目类别:
Cancer Cell Biology and Signaling Research Program
癌细胞生物学和信号传导研究计划
  • 批准号:
    10470109
  • 财政年份:
    2013
  • 资助金额:
    $ 31.88万
  • 项目类别:
Cancer Cell Biology and Signaling Research Program
癌细胞生物学和信号传导研究计划
  • 批准号:
    10204890
  • 财政年份:
    2013
  • 资助金额:
    $ 31.88万
  • 项目类别:
Regulation of Cell Survival and Tumor Progression by Akt
Akt 对细胞存活和肿瘤进展的调节
  • 批准号:
    7258352
  • 财政年份:
    2005
  • 资助金额:
    $ 31.88万
  • 项目类别:
Regulation of Cell Survival and Tumor Progression by Akt
Akt 对细胞存活和肿瘤进展的调节
  • 批准号:
    6964934
  • 财政年份:
    2005
  • 资助金额:
    $ 31.88万
  • 项目类别:
Regulation of Cell Survival and Tumor Progression by Akt
Akt 对细胞存活和肿瘤进展的调节
  • 批准号:
    7424938
  • 财政年份:
    2005
  • 资助金额:
    $ 31.88万
  • 项目类别:
Regulation of Cell Survival and Tumor Progression by Akt
Akt 对细胞存活和肿瘤进展的调节
  • 批准号:
    7617853
  • 财政年份:
    2005
  • 资助金额:
    $ 31.88万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了